Allogeneic hemopoietic stem cell transplantation (BMT) after IV busulfan, and cyclophosphamide (BuCy) for acute myeloid leukemia (AML) and myelodysplasia (MDS).

被引：0
|
作者：
Andersson, BS
Cagnoni, P
Jones, R
Gian, V
Wingard, JR
Tarantolo, S
Kashyap, A
Forman, SJ
Hu, WH
Blume, KG
Fernandez, HF
Champlin, RE
机构：
[1] Univ Colorado, Boulder, CO 80309 USA
[2] Univ Florida, Gainesville, FL 32611 USA
[3] Univ Nebraska, Lincoln, NE 68583 USA
[4] Univ Miami, Coral Gables, FL 33124 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
729
引用
收藏
页码：167A / 167A
页数：1
相关论文
共 50 条
  • [1] IV busulfan, cyclophosphamide (BuCy) and allogeneic hemopoietic stem cells (BMT) for chronic myeloid leukemia (CML).
    Andersson, BS
    McWilliams, K
    Tran, H
    Fernandez, H
    Cagnoni, P
    Jones, R
    Gian, V
    Tarantolo, S
    Kashyap, A
    Forman, SJ
    Hu, WW
    Blume, KG
    Champlin, RE
    BLOOD, 1998, 92 (10) : 285A - 285A
  • [2] Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
    Andersson, BS
    Gajewski, J
    Donato, M
    Giralt, S
    Gian, V
    Wingard, J
    Tarantolo, S
    Fernandez, H
    Hu, WW
    Blume, K
    Kashyap, A
    Forman, SJ
    Champlin, RE
    BONE MARROW TRANSPLANTATION, 2000, 25 (Suppl 2) : S35 - S38
  • [3] Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
    BS Andersson
    J Gajewski
    M Donato
    S Giralt
    V Gian
    J Wingard
    S Tarantolo
    H Fernandez
    WW Hu
    K Blume
    A Kashyap
    SJ Forman
    RE Champlin
    Bone Marrow Transplantation, 2000, 25 : S35 - S38
  • [4] Thiotepa, busulfan and cyclophosphamide as intensified conditioning in myelodysplasia (MDS) or secondary acute myeloid leukemia (sAML) undergoing allogeneic stem cell transplantation
    Runde, V
    Retzlaff, S
    Beelen, DW
    Schaefer, UW
    BONE MARROW TRANSPLANTATION, 1999, 23 : S153 - S153
  • [5] Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS
    Chu, Diem
    Valdez, Ben C.
    Fox, Patricia S.
    Thall, Peter
    Worth, Laura
    Popat, Uday R.
    Jones, Roy B.
    Shpall, Elizabeth J.
    Hosing, Chitra
    Alousi, Amin M.
    Rondon, Gabriela
    Kebriaei, Partow
    Champlin, Richard E.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S152 - S153
  • [6] CLOFARABINE ± FLUDARABINE AND IV BUSULFAN WITH ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADVANCED MYELOID LEUKEMIA (ML) AND MDS
    Andersson, B. S.
    Valdez, B. C.
    Thall, P. F.
    Wang, X.
    Worth, L. L.
    Popat, U.
    Alousi, A.
    Hosing, C.
    Jones, R. B.
    Shpall, E. J.
    de Lima, M.
    Champlin, R. E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S293 - S293
  • [7] Phase II study of targeted busulfan(BU) and cyclophosphamide(CY) as conditioning for allogeneic hemopoietic stem cell transplantation (HSCT) in patients with myelodysplasia (MDS).
    Getzendaner, L
    Storer, B
    Anasetti, C
    Slattery, J
    Chauncey, T
    Storb, R
    Hansen, J
    Sanders, J
    Appelbaum, F
    Deeg, J
    BLOOD, 2000, 96 (11) : 584A - +
  • [8] Busulfan and melphalan as preparative therapy for stem cell transplantation in pediatric patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS)
    Andreansky, M
    Fiederlein, R
    Graham, ML
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 85 - 85
  • [9] OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA AFTER CONDITIONING WITH BUSULFAN, CYCLOPHOSPHAMIDE, AND ETOPOSIDE
    Ayas, Mouhab
    Belgaumi, Assim
    Al-Seraihy, Amal
    Al-Jefri, Abdullah
    Al-Ahmari, Ali
    Al-Mahr, Mohammed
    Khairy, Ashraf
    Markiz, Samer
    El-Soth, Hassan
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 816 - 816
  • [10] IV busulfan (Busulfex™), cytoxan (BuCy) and allogeneic hemopoietic stem cell transplantation (HSCT) for advanced hematological malignancies.
    Andersson, BS
    Giralt, S
    Tran, H
    McWilliams, K
    Gian, V
    Wingard, J
    Fernandez, H
    Tarantolo, S
    Kashyap, A
    Forman, SJ
    Hu, W
    Blume, K
    Cagnoni, P
    Jones, R
    Kantarjian, H
    Champlin, RE
    BONE MARROW TRANSPLANTATION, 1999, 23 : S69 - S69
12345